Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celgene’s Oral Mongersen Could Be Game-Changer In Crohn’s Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

New England Journal of Medicine editorial says that if Phase II results for Celgene’s oral antisense candidate mongersen (GED-0301) are confirmed, the drug’s durable effect “would be unprecedented and would represent a first step toward curing the disease.”

You may also be interested in...



J.P. Morgan Notebook, Jan. 12: Biogen, Novartis, Celgene

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Rare Disease Roundtable: How Rare Is Too Rare?

Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS078287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel